Kura Oncology Stock Today

KURA
 Stock
  

USD 13.07  0.59  4.32%   

Market Performance
0 of 100
Odds Of Distress
Less than 1
Kura Oncology is trading at 13.07 as of the 4th of October 2022, a -4.32 percent down since the beginning of the trading day. The stock's open price was 13.66. Kura Oncology has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Kura Oncology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of September 2022 and ending today, the 4th of October 2022. Click here to learn more.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 66.56 M outstanding shares of which 5.31 M shares are now shorted by private and institutional investors with about 6.69 trading days to cover. More on Kura Oncology
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Kura Oncology Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Kura Oncology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Kura Oncology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Kura Oncology generated a negative expected return over the last 90 days
Kura Oncology has high historical volatility and very poor performance
Net Loss for the year was (132.22 M) with profit before overhead, payroll, taxes, and interest of 0.
Kura Oncology currently holds about 480.08 M in cash with (108.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.2.
Latest headline from www.marketscreener.com: KURA ONCOLOGY, INC. Change in Directors or Principal Officers - Marketscreener.com
ChairmanTroy Wilson
Average Analyst Recommendation
Analysts covering Kura Oncology report their recommendations after researching Kura Oncology's financial statements, talking to executives and customers, or listening in on Kura Oncology's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Kura Oncology. The Kura Oncology consensus assessment is calculated by taking the average forecast from all of the analysts covering Kura Oncology.
Strong Buy5 Opinions
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Kura Oncology's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
Kura Oncology (KURA) is traded on NASDAQ Exchange in USA and employs 117 people. The company currently falls under 'Small-Cap' category with current market capitalization of 885.86 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kura Oncology's market, we take the total number of its shares issued and multiply it by Kura Oncology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Kura Oncology conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 66.56 M outstanding shares of which 5.31 M shares are now shorted by private and institutional investors with about 6.69 trading days to cover. Kura Oncology currently holds about 480.08 M in cash with (108.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.2.
Check Kura Oncology Probability Of Bankruptcy
Ownership
Kura Oncology holds a total of 66.56 Million outstanding shares. The majority of Kura Oncology outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kura Oncology to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kura Oncology. Please pay attention to any change in the institutional holdings of Kura Oncology as this could imply that something significant has changed or about to change at the company. Also note that almost two million six hundred sixty-two thousand four hundred invesors are currently shorting Kura Oncology expressing very little confidence in its future performance.

Ownership Allocation (%)

Check Kura Oncology Ownership Details

Kura Oncology Stock Price Odds Analysis

What are Kura Oncology's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Kura Oncology jumping above the current price in 90 days from now is about 89.77%. The Kura Oncology probability density function shows the probability of Kura Oncology stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Kura Oncology has a beta of 0.5699. This indicates as returns on the market go up, Kura Oncology average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Kura Oncology will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Kura Oncology is significantly underperforming DOW.
  Odds Below 13.07HorizonTargetOdds Above 13.07
10.17%90 days
 13.07 
89.77%
Based on a normal probability distribution, the odds of Kura Oncology to move above the current price in 90 days from now is about 89.77 (This Kura Oncology probability density function shows the probability of Kura Oncology Stock to fall within a particular range of prices over 90 days) .

Kura Oncology Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Kura Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kura Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kura Oncology's value.
InstituionSecurity TypeTotal SharesValue
Ecor1 Capital LlcCommon Shares6.6 M121.7 M
Blackrock IncCommon SharesM91 M
View Kura Oncology Diagnostics

Kura Oncology Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Kura Oncology market risk premium is the additional return an investor will receive from holding Kura Oncology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Kura Oncology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Kura Oncology's alpha and beta are two of the key measurements used to evaluate Kura Oncology's performance over the market, the standard measures of volatility play an important role as well.

Kura Oncology Stock Against Markets

Picking the right benchmark for Kura Oncology stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Kura Oncology stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Kura Oncology is critical whether you are bullish or bearish towards Kura Oncology at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kura Oncology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio File Import Now

   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module

Kura Oncology Corporate Directors

Kura Oncology corporate directors refer to members of a Kura Oncology board of directors. The board of directors generally takes responsibility for the Kura Oncology's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Kura Oncology's board members must vote for the resolution. The Kura Oncology board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Steven Stein - DirectorProfile
Thomas Malley - DirectorProfile
Mary Szela - DirectorProfile
Faheem Hasnain - Independent DirectorProfile

Invested in Kura Oncology?

The danger of trading Kura Oncology is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Kura Oncology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Kura Oncology. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Kura Oncology is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please see Correlation Analysis. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for analysis

When running Kura Oncology price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine Kura Oncology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.